Noreen Nazir

Dr. Noreen Nazir


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 January 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
SSSaagar Sanghvi
Saagar Sanghvi
LSLogan S. Schwarzman
Logan S. Schwarzman
NNNoreen Nazir
Noreen Nazir
Myocardial injury is a common complication of the COVID-19 illness and is associated with a worsened prognosis. Systemic hyperinflammation seen in the advanced stage of COVID-19 likely contributes to myocardial injury. Cardiac magnetic resonance imaging (CMR) is the preferred imaging modality for non-invasive evaluation in acute myocarditis, enabling risk stratification and prognostication. Modified scanning protocols in the pandemic setting reduce risk of exposure while providing critical data regarding cardiac tissue inflammation and fibrosis, chamber remodeling, and contractile function. The growing use of CMR in clinical practice to assess myocardial injury will improve understanding of the acute and chronic sequelae of myocardial inflammation from various pathological etiologies.

4 August 2021 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
AKAbha Khandelwal
Abha Khandelwal
MBMay Bakir
May Bakir
MBMeghan Bezaire
Meghan Bezaire
BCBriana Costello
Briana Costello
JGJoanne Michelle D. Gomez
Joanne Michelle D. Gomez
AVAnnabelle Santos Volgman
Annabelle Santos Volgman

8 May 2015 in Clinical Cardiology
Verified
Journal Article
Open access
PDF file
RDRami Doukky
Rami Doukky
KHKathleen Hayes
Kathleen Hayes
NFNathan Frogge
Nathan Frogge
NNNoreen Nazir
Noreen Nazir
FCFareed M. Collado
Fareed M. Collado
KWKim Allan Williams
Kim Allan Williams
Background: The impact of health insurance carrier and socioeconomic status (SES) on the adherence to appropriate use criteria (AUC) for radionuclide myocardial perfusion imaging (MPI) is unknown.Hypothesis: Health insurance carrier's prior authorization and patient's SES impact adherence to AUC for MPI in a fee‐for‐service setting.Methods: We conducted a prospective cohort study of 1511 consecutive patients who underwent outpatient MPI in a multi‐site, office‐based, fee‐for‐service setting. The patients were stratified according to the 2009 AUC into appropriate/uncertain appropriateness and inappropriate use groups. Insurance status was categorized as Medicare (does not require prior authorization) vs commercial (requires prior authorization). Socioeconomic status was determined by the median household income in the ZIP code of residence.Results: The proportion of patients with Medicare was 33% vs 67% with commercial insurance. The rate of inappropriate use was higher among patients with commercial insurance vs Medicare (55% vs 24%; P < 0.001); this difference was not significant after adjusting for confounders known to impact AUC determination (odds ratio: 1.06, 95% confidence interval: 0.62‐1.82, P = 0.82). The mean annual household income in the residential areas of patients with inappropriate use as compared to those with appropriate/uncertain use was $72 000 ± 21 000 vs $68 000 ± 20 000, respectively (P < 0.001). After adjusting for covariates known to impact AUC determination, SES (top vs bottom quartile income area) was not independently predictive of inappropriate MPI use (odds ratio: 0.9, 95% confidence interval: 0.53‐1.52, P = 0.69).Conclusions: Insurance carriers prior authorization and SES do not seem to play a significant role in determining physicians adherence to AUC for MPI.

14 September 2022 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
AAAvi Aronov
Avi Aronov
YKYoo Jin Kim
Yoo Jin Kim
NSNadera J Sweiss
Nadera J Sweiss
NNNoreen Nazir
Noreen Nazir
Although rheumatoid arthritis (RA) results in a 50% increased risk of cardiovascular disease mortality, comparable to the risk associated with diabetes mellitus, a significant care gap remains in cardiovascular risk management for this high-risk population. A retrospective cohort study was conducted at a minority-serving institution to assess demographic, clinical, and laboratory data associated with referral to cardiology by rheumatology. The results showed that a minority (5%) of patients were referred to cardiology during an outpatient rheumatology encounter. Patients referred were more likely to be on antihypertensive medication and aspirin. Differences in traditional cardiovascular risk factors such as systolic blood pressure, LDL cholesterol, smoking history, and diabetes mellitus were not significantly associated with being referred. Patients with RA who were evaluated by cardiology were more likely to be started on cardiovascular risk-reducing medications such as antihypertensive, lipid-lowering, and aspirin therapy. This study highlights a care gap in the evaluation and referral of patients with RA and recognizes the improved preventive cardiovascular care received by patients evaluated by a cardiologist.

1 May 2025 in American Journal of Preventive Cardiology
Verified
Journal Article
Open access
AAAvi G. Aronov
Avi G. Aronov
YKYoo Jin Kim
Yoo Jin Kim
SZSalman Zahid
Salman Zahid
EMErin D. Michos
Erin D. Michos
NNNoreen Nazir
Noreen Nazir
Patients with rheumatoid arthritis (RA) face an increased risk of cardiovascular disease (CVD) that traditional risk factors alone cannot fully explain. Chronic inflammation may influence lipid profiles and contribute to this risk. This study evaluates predictors of incident CVD in RA and explores how erythrocyte sedimentation rate (ESR) modifies the relationship between lipid levels and CVD outcomes. This retrospective cohort study included 1,802 RA patients aged 40-79 years, diagnosed between 2015 and 2022, and free of CVD at diagnosis. We evaluated the association between traditional cardiovascular risk factors—including current smoking, diabetes mellitus, systolic blood pressure, body mass index (BMI), HDL cholesterol, and LDL cholesterol—and RA-specific inflammatory markers, including ESR and C-reactive protein (CRP), with the incidence of CVD. Cox proportional hazards models adjusted for age, sex, race/ethnicity, antihypertensive medications, lipid-lowering medications, and antiplatelet medications. During a median follow-up of 3.5 years, 187 patients (10.4 %) developed CVD. The mean BMI was 32 kg/m² (standard deviation [SD] 10), HDL cholesterol was 53 mg/dL (SD 17), and LDL cholesterol was 104 mg/dL (SD 37). The median ESR was 21 mm/hr (interquartile range [IQR] 11–42) and CRP was 6 mg/L (IQR 3–12). Higher LDL cholesterol was inversely associated with CVD risk (HR 0.77 per SD increase, 95 % CI 0.63–0.94), with this association weakening with increasing ESR levels (interaction term HR 0.84, 95 % CI 0.71–0.99). Elevated HDL cholesterol also showed significantly decreased CVD risk (HR 0.82 per SD increase, 95 % CI 0.68–0.97). Smoking and diabetes were associated with increased risks (HR 1.52, 95 % CI 1.07–2.17 and HR 2.08, 95 % CI 1.39–3.10, respectively). This study highlights the complex interplay between lipid levels and inflammation in RA, highlighting the nuances of CVD risk assessment in RA.

27 November 2024 in JACC: Advances
Verified
Journal Article
Open access
MAMohammed Abozenah
Mohammed Abozenah
NNNoreen Nazir
Noreen Nazir
NSNishtha Sareen
Nishtha Sareen
EBEric Brandt
Eric Brandt
QPQuinn R. Pack
Quinn R. Pack
EYEugene Yang
Eugene Yang
The tobacco epidemic has claimed countless lives, caused significant morbidity, and cost billions of dollars in direct costs and lost productivity. Despite its acute vascular effects, nicotine alone has not been definitively linked to cardiovascular events. Rather, additives found in cigarettes and other tobacco products likely play a bigger role in tobacco’s link to cardiovascular events. The emergence of electronic nicotine delivery systems introduces a new challenge, particularly among certain groups. Understanding the groups vulnerable to tobacco product use, identifying factors that influence this vulnerability, and examining different approaches to mitigating these factors is imperative to curbing the detrimental effects of the tobacco epidemic. Ameliorating screening and treatment efforts will require collaborative efforts that involve clinicians, health care systems, local and regional communities, government agencies, policymakers, and medical societies.